ViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore Sequencing

OXFORD, England & VIENNA--(BUSINESS WIRE)-- #Nanopore--ViruSure, an Asahi Kasei company and global leader in pathogen safety testing for biopharmaceuticals, today announced the launch of the world's first GMP-validated adventitious viral agent (AVA) detection test based on Oxford Nanopore sequencing. Designed for use in regulated biopharmaceutical quality control (QC) environments, this process is designed to ensure biologics medicines are free from viral contamination. The first-in-class solution combines.